

This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



August 7, 2023

Company name: Modalis Therapeutics Corporation

Stock exchange listing: Tokyo Stock Exchange

Code number: 4883

URL: <https://www.modalistx.com/en/>

Representative: Haruhiko Morita

### **Notice Regarding the Recording of Non-Operating Income and Extraordinary Loss**

Modalis Therapeutics Corporation (hereafter, “the Company”) hereby announces the recording of non-operating income (foreign exchange income) and extraordinary loss (impairment loss) for the six months ended June 30, 2023 (January 1 – June 30, 2023).

#### **1. Details of non-operating income (foreign exchange income)**

For the six months ended June 30, 2023, the Company recorded foreign exchange income of 54,637 thousand yen as non-operating income due to fluctuations in foreign exchanges rates. This was mainly attributed to foreign exchange income arising from revaluation of foreign currency denominated assets and liabilities of the Company.

#### **2. Details of and extraordinary loss**

For the six months ended June 30, 2023, the Company recorded impairment loss on fixed assets of 37,146 thousand yen as an extraordinary loss. This was recorded in accordance with the "Accounting Standard for Impairment of Fixed Assets" because the Company is in the research and development phase of its pharmaceuticals business, and therefore, the profit and loss arising from operating activities is continuously negative, and future projections are highly uncertain in terms of profitability considering the characteristics of the business.

#### **3. Impact on earnings**

Regarding the impact of the non-operating income (foreign exchange income) on earnings, please refer to “Consolidated Financial Results for the Six Months Ended June 30, 2023 (Japanese GAAP)” disclosed on August 7, 2023.